ArticleGenes2025

Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer.

Amy Rees et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.